Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib versus crizotinib as first-line monotherapy for advanced ALK-positive non-small cell lung cancer
2023-509169-19-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Jul 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) and ALK-positive non-small cell lung cancer comparing Lorlatinib monotherapy with Crizotinib monotherapy (2 arms). Primary endpoint: Progression-free survival. Planned start Jul 2017; status: authorised.
02
Drugs
lorlatinibcrizotinib
03
Conditions
non-small cell lung cancer (NSCLC)ALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on 2023-509169-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509169-19-00.